Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2023 Results Conference Call August 14, 2023 8:30 AM ET

Company Participants

Nichol Ochsner - Vice President of Investor Relations

Christal Mickle - Co-Founder, Chief Product Development Officer and Interim CEO

LaDuane Clifton - Chief Financial Officer

Josh Schafer - Chief Commercial Officer and Executive Vice President, Business Development

Conference Call Participants

Oren Livnat - H.C. Wainwright

Sumant Kulkarni - Canaccord

Jonathan Aschoff - ROTH MKM

Operator

Good morning, and welcome to the Zevra Therapeutics Second Quarter 2023 Corporate and Financial Results Conference Call. [Operator Instructions] Please be advised that today's call is being recorded.

I will now turn the call over to Nichol Ochsner, Zevra Therapeutics Vice President, Investor Relations and Corporate Communications. Thank you. You may begin.

Nichol Ochsner

Good morning, and thank you for joining us today to review Zevra Therapeutics progress in the second quarter of 2023, outlining our clinical progress, operational achievements, and financial results. Before we get started, let me take a moment to provide some important information. First, I encourage you to access the webcast slides and the press release both of which were released this morning and are available in the Investors Section of Zevra's website. These documents provide comprehensive insights into our results for this quarter. As we move forward with the presentation, it is important to highlight that today's discussions will include forward-looking statements.

These encompass various topics, including updates on clinical development, and regulatory journey of arimoclomol, the achievements and revenue milestones of AZSTARYS, and our French Early Access Program or EAP program. The achievement of our pipeline programs, time lines for clinical trial enrollment, initiation, completion and data reporting from our clinical trials. However, forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties and other significant factors that may lead to actual results differing materially from those projections made.

For a comprehensive understanding of these factors, please refer to the Risk Factors section of our annual report on Form 10-K. I am pleased to welcome Zevra's management team members participating in today's call.

I'm joined by Christal Mickle, our Co-Founder, Chief Development Officer and interim Chief Executive Officer. LaDuane Clifton, our Chief Financial Officer; and Josh Schafer, our Chief Commercial Officer and Executive Vice President of Business Development.

Now I'd like to turn the call over to Christal Mickle.

Christal Mickle

Thank you, Nichol. Good morning, and thank you all for joining us today. The year-to-date has been a dynamic time for Zevra and second quarter was quite productive for our team. We're very encouraged by the continued advancement of our rare disease pipeline programs towards multiple near-term clinical and regulatory milestones as well as by the progress that we are making to add in-house commercial capabilities needed to bring therapies to market directly. In addition, we continue to enhance our patient advocacy efforts, which include ongoing support of our early access programs for arimoclomol.